PRESS RELEASE

July 18, 2022
ETERN Announces Clinical Trial Collaboration with Merck to Evaluate ET0038 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
October 14, 2021
ETERN Won the "Excellent Enterprise" Award of the 10th China Innovation & Entrepreneurship Competition Biomedical Section
September 1, 2021
ETERN Therapeutics Announces Completion of Series B Financing to Advance the Protein Liquid-Liquid Phase Separation Technology Platform and Accelerate the Development of Novel Drugs to Target “Undruggable” Proteins
July 2, 2021
ET0038, a selective allosteric inhibitor of SHP2, has received the IND approval in Mainland China
May 18, 2021
ET0038, a highly potent and selective allosteric inhibitor of SHP2, received U.S. FDA IND approval